Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, Scottish Biomedical

GE Healthcare's Q3 Revenues Rise 9 Percent as Earnings Jump 19 Percent
GE Healthcare this week said that third-quarter revenues climbed 9 percent as earnings increased 19 percent.
For the quarter ended Sept. 30, GE Healthcare generated $3.9 billion in revenues, up from $3.6 billion during the same quarter in 2005.
GE Healthcare's earnings for the quarter increased to $700 million from $589 million in the third quarter of 2005.
GE's total revenues for the quarter were $40.9 billion, up from $36.4 billion during the same period last year.
GE did not break out its research and development expenses for the Healthcare segment.
As of Sept. 30, GE reported $59.4 billion in cash and marketable securities.

Drug-Discovery CRO Says HCS Will Gain Momentum
High-content screening “is set to overtake current methods as the preferred technique of generating hits with the greatest interest coming from the oncology sector,” according to a news report.

According to Outsourcing, Stephen Hammond, CEO of Scottish Biomedical, a Glasgow based pre-clinical drug-discovery services company, said that HCS' “accuracy and speed of data capture” are “deciding factors when studying cell models.”

Hammond was quoted as saying that at least 50 percent of all drug discovery assays performed now are cell-based, with a major marketing push by outsourcing companies suggesting that cell-based HCS as the way to overcome present hurdles.
“HCS has many advantages over biochemical assays in that there is no need to purify the target which can affect assay sensitivity,” Hammond was quoted as saying.
Hammond also said that HCS has some challenges. “The disadvantages of HCS are primarily assay development, costs and relative complexity,” he was quoted as saying.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.